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Abstract 
Evidences suggest that omega-3 fatty acid (n−3 PUFA) metabolism is imbalanced 
in apolipoprotein E epsilon 4 isoform carriers (APOE4). This study aimed to investigate 
APOE genotype-dependant modulation of FA profiles, protein and enzyme important to 
fatty acid (FA) metabolism in the adipose tissue, the liver and the plasma using human 
APOE-targeted replacement mouse-model (N = 37). FA transport (FATP) and binding 
(FABP) protein levels in tissues and concentrations of liver carnitine palmitoyltransferase 
1 (CPT1) were performed. N-3 PUFA concentration was >45% lower in the adipose 
tissue and liver of APOE4 mice compared to APOE3 mice. In APOE4 mice, there were 
higher levels of FATP and FABP in the liver and higher FATP in the adipose tissue 
compared to APOE2 mice. There was a trend towards higher CPT1 concentrations in 
APOE4 mice compared to APOE3 mice. Therefore, since APOE-isoform differences 
were not always in line with the unbalanced n‒3 PUFA profiles in organs, other proteins 
may be involved in maintaining n‒3 PUFA homeostasis in mice with different APOE-
isoforms.  
Keywords: Transport and binding proteins, n3 PUFA metabolism, cellular FA uptake 
and degradation, APOE4 carriers. 
Abbreviations used: AA, arachidonic acid; Ab, antibody; AD, Alzheimer’s disease; 
ALA, alpha-linolenic acid; ApoE, apolipoprotein E; CPT1, Carnitine 
palmitoyltransferase 1; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, 
fatty acid; FABP, fatty acid binding protein; FATP, fatty acid transport protein; LCFA, 
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1. INTRODUCTION 
Fatty acids (FA), notably long-chain fatty acids (LCFA) such as docosahexaenoic 1 
acid (DHA, 22:6), are essentials for brain growth as well as for brain health maintenance 2 
[1]. Imbalance in FA metabolism has been associated with neurological diseases such as 3 
depression and Alzheimer’s disease (AD) [2]. AD is the most common type of dementia 4 
(around 5060% of all cases) and ranked fifth as leading cause of death in American 5 
population aged 65 years and over [3]. This disease results from a combination of non-6 
modifiable factors (i.e. genetic factors) and reversible factors such as diet [4]. Most 7 
important genetic risk factor of AD is carrying one or two allele(s) of the apolipoprotein 8 
E 4 (APOE4) [5-7]. Fatty fish intake containing omega-3 FA (n3 PUFA), such as DHA 9 
is suggested to reduce the risk of developing AD but this link seems to hold only in the 10 
non-carriers of APOE4 [5-7]. Moreover, compared to non-carriers of APOE4 (i.e. APOE2 11 
and APOE3), consumption of n3 PUFA, such as DHA, fails to reduce the risk of 12 
cognitive decline among APOE4 carriers [5, 8]. This could potentially be explained by a 13 
disturbed DHA metabolism in APOE4 carriers, supported by lower DHA content in the 14 
brain of APOE4 animals and humans [9, 10].  15 
Higher levels of DHA have also been reported in the plasma of human carrying 16 
the APOE4 allele [11, 12]. However, the mechanisms explaining why DHA homeostasis 17 
could be imbalanced in APOE4 carriers are still unknown. One hypothesis is that APOE 18 
genotype modulates expression of key fatty acid handling proteins thereby impairing 19 
transport and uptake of FA by peripheral organs such as adipose tissue and liver. These 20 
two tissues are important players in lipid metabolism because they constantly exchange 21 
FA with blood. Therefore, plasma FA profile pictures the balance of uptake and release 22 
of FA from hepatic and adipose cells [13]. Key proteins are involved in the transport, 23 
release and uptake of plasma FA towards peripheral organs:  fatty acid transport proteins 24 
(FATP) and fatty acid binding proteins (FABP). FATPs are transmembrane transport 25 
proteins necessary for efficient uptake of FA by cells [14]. Once bound to FATPs, FABPs 26 
act as chaperon proteins to reduce the hydrophobic nature of LCFAs and ease their 27 
transport within the cells towards specific metabolic routes [15, 16]. For example, upon 28 
activation by hepatic acyl-CoA synthase, newly formed LCFA-CoAs are trapped inside 29 
hepatocytes and may be directed by FABP toward the mitochondria for β-oxidation to 30 
produce energy [17]. Carnitine palmitoyltransferase 1 (CPT1) is currently recognized as 31 
the key limiting enzyme initiating FA oxidation [18]. Overall, FATPs and FABPs 32 
regulate LCFA transport, uptake and release by tissues, as CPT1 regulates their 33 
catabolism [2, 14, 15, 18]. FATP1 and FABP4 are mainly found in adipose tissue 34 
whereas FATP5 and FABP1 are highly expressed in the liver [14, 15]. FATPs and 35 
FABPs partner together for efficient LCFA uptake by cells [19]. 36 
The aim of the present study was to investigate whether APOE genotypes disrupt 37 
FA profile in the adipose tissue and the liver and whether this is explained by different 38 
level of FABPs, FATPs and CTP1 in these tissues.  39 
2. METHODS 
2.1 Animals 
Male and female APOE-targeted replacement mice expressing human APOE genotypes 40 
were purchase at Taconic (Hudson, NY). Animals were breed in order to obtain colonies 41 
of mice homozygous for human APOE2, APOE3, or APOE4 on a C57/BL6 background 42 
(N=10‒14/genotype group). This mouse model was first created by Sullivan et al [20] to 43 
study human APOE3 phenotype in vivo and is currently recognized as a useful in vivo 44 
model to study the role of human apoE on lipid metabolism. APOE-targeted replacement 45 
mice have phenotypes similar to those found in humans [21], such as high blood 46 
cholesterol and LDL-cholesterol levels in APOE4 mice and high levels of plasma 47 
triglycerides and cholesterol in APOE2 mice [22]. 48 
From weaning to 4-month of age, mice were fed a commercial chow diet to 49 
prevent any neurodevelopmental problems coming from dietary deficiency. At 4-month 50 
of age, mice were switched to a low-fat diet (low n3 PUFA/n6 PUFA) until sacrifice. 51 
The low-fat diet had the following composition: 66.0% (w/w) of proteins, 20.3% (w/w) 52 
of carbohydrates and 5.0% (w/w) of lipids (Table 1). In order to investigate the influence 53 
of age on n3 PUFA metabolism according to APOE genotype, necropsies was 54 
performed on mice of either 8.5 or 12-months of age. At sacrifice, mice were perfused in 55 
the heart with 50 ml of ice-cold 0.1 M PBS buffer after deep anesthesia with 56 
ketamine/xylazine. The adipose tissue, the liver and the plasma were collected within 57 
minutes and rapidly frozen on dry ice. Organs and plasma were stored at 80C until 58 
further analysis. The animal protocol was performed in accordance with the Canadian 59 
Council on Animal Care and was approved by the Comité d'éthique de la recherche du 60 
CHUQ-Centre hospitalier de l'Université Laval. 61 
2.2 Fatty acid analysis 
Total lipids were extracted from adipose tissue (10 mg), liver (100 mg) and 62 
plasma (100 µL), using 2:1 chloroformmethanol as described by Folch et al. [23]. 63 
Lipids were extracted from organs in a glass potter and from plasma in a glass tube. After 64 
collecting the organic phase, total lipids were saponified for releasing the FA from 65 
cholesteryl esters and glycerolipids [10]. Non-esterified FAs were thereafter 66 
transmethylated using 14% boron trifluoridemethanol (Sigma, St. Louis, MO). FA 67 
profiles were determined by gas chromatography as previously described [24]. 68 
2.3 Proteins and Western blot analysis 
Total proteins were extracted from adipose tissue and liver and homogenized 69 
using glass potters in a solution containing 50 mM TrisHCL (pH = 7.4), 2.5 mM EDTA, 70 
150 mM NaCl, 1% Triton and a freshly added protease inhibitor cocktail (Roche 71 
Diagnostics, Indianapolis, IN). After 15 min on ice, samples were centrifuged at 13,000 72 
rpm for 15 min at 4C. Protein concentrations were assessed using bicinchoninic acid 73 
(BCA) Protein Assay kit (Thermo Fisher Scientific Inc., Waltham, MA). 15 µg of 74 
proteins were denatured with SDS blue buffer (New England Biolabs, Ipswich, MA), 75 
loaded on a 10% sodium dodecyl sulfate-polyacrylamide electrophoresis gel and 76 
transferred onto a 0.2 µM polyvinylidene difluoride (PVDF) membrane (BioRad, ON, 77 
Canada). Membranes were blocked with 5% milk0.01% TBS-Tween (TBST) for 30 min 78 
at room temperature, then incubated overnight at 4C with primary antibodies (Ab) 79 
against FATP1 (1:1000, Abcam Inc., Cambridge, MA), FABP4 (1:1000, Cayman 80 
Chemical, Ann Arbor, MI), FATP5 (1:500, Santa Cruz Biotechnology Inc., Dallas, TX), 81 
FABP1 (1:1000, Cell Signaling Technology, Danvers, MA) and -actin (1:10000, Cell 82 
Signaling Technology, Danvers, MA). Membranes were washed with TBST, 83 
immunoblotted with a horseradish peroxidase linked secondary anti-rabbit Ab (1:10000, 84 
Cell Signaling Technology, Danvers, MA) followed by chemiluminescence reagents 85 
(chemiluminescence ECL kits, Perkin Elmer, Waltham, MA). Densitometry was 86 
analyzed using ImageJ software (U.S. National Institutes of Health) and results were 87 
expressed in ratio to -actin. 88 
2.4 Liver CPT1 quantification 
Liver samples were weighed before homogenization. Livers (100 mg) were 89 
homogenized in 1 mL of 1X PBS buffer (pH = 7.4) using an eppendorf micropestle. The 90 
resulting suspension was sonicated for a total of 3 × 5 sec cycles to break cell membranes 91 
and then centrifuged at 5,000 × g for 5 min at 4C. Supernates were removed, diluted 92 
(1:500 and 1:800) and assay immediately. Liver CPT1 isoform A levels were analyse 93 
using a highly sensitive (1.56 pg/mL) and quantitative sandwich enzyme-linked 94 
immunosorbant assay (ELISA) test kit for mouse CPT1 liver isoform enzyme (CPT1a; 95 
Cusabio, Wuhan, China; [CV%] < 10 %). All standards and samples were assayed in 96 
duplicate. Average of duplicate readings was used for calculating concentrations using a 97 
four parameter logistic (4-PL) curve-fit model (MasterPlex ® EX expression analysis 98 
module, Hitachi Software, San-Francisco, CA). 99 
2.5 Statistical analysis 
Normal distribution and homogeneity of variance were evaluated by performing 100 
Levene’s test (parametric or non-parametric) before further statistical analysis. All data 101 
were analysed for statistical differences using ANOVA or Kruskal-Wallis non-parametric 102 
analysis of variance in SPSS version 22.0 (IBM Corp., Armonk, NY). When significant 103 
differences were found, pairwise comparisons (Fisher’s LSD or Mann-Whitney U tests) 104 
were performed in order to assess statistical differences between genotype groups. 105 
Pearson correlations and multiple regression models were used to investigate associations 106 
between tissue-specific levels of FA handling proteins (FABPs and FATPs) and 107 
concentration in LCFAs. The average of duplicate readings for each liver homogenate 108 
samples was used to asses CTP1 concentrations according to APOE genotype. P values < 109 
0.05 were considered statistically significant, and P values for trends were set as < 0.08. 110 
Data are presented as means ± SEMs or as % compared to control mice, namely APOE3 111 
(Equation 1). 112 
 
Equation 1: 
Compared to control (%) = (APOE4 ÷ APOE3) × 100 
113 
3. RESULTS 114 
3.1 Mice groups 115 
 The study groups had N=10 APOE2 mice, N=13 APOE3 mice, N=14 APOE4 116 
mice and of N=8 Wild-type C57BL/6 mice. At sacrifice, the mean weight for APOE2 117 
mice was 43.2 g ± 7.6 g, 37.2 g ± 7.0 g for APOE3, 34.5 g ± 6.7 g for APOE4 and 44.8 g 118 
± 6.0 g for Wild-Type mice. There was no age-difference in any of the studied outcomes, 119 
thus mice of 8.5 or 12-months of age were pooled by APOE genotype in further analysis. 120 
3.2 Fatty acid profiles 
FA profile of the adipose tissue (Table 2), the liver (Table 3) and the plasma 121 
(Table 4) of transgenic mice was modified by APOE genotype. There were limited 122 
differences in the FA profile of adipose tissue, liver and plasma of APOE3 mice, 123 
compared to Wild-type C57BL/6 mice (WT). APOE3 mice were henceforth designated as 124 
the control group since they express the most common APOE isoform and this allele is 125 
not associated to any human disease [21].  126 
In the adipose tissue of APOE4 mice, alpha-linolenic (ALA; 18:3 n‒3) and DHA 127 
were both significantly lower than in APOE3 mice, whereas 16:1 n‒7 was significantly 128 
higher (Table 2). In the adipose tissue and the liver of APOE4 mice, ALA levels were 129 
respectively 56% (P = 0.036) and 14% (P < 0.001) the levels of APOE3 mice. In the liver 130 
of APOE4 mice, DHA was 66% lower than the level of APOE3 mice. All other fatty 131 
acids measured in the liver did not differ according to APOE genotype. In the adipose 132 
tissue and the liver of APOE4 mice, n3 PUFA concentrations were 53% lower 133 
compared to APOE3 mice (P values ≤ 0.003). Total FA concentration in the plasma of 134 
APOE2 mice was approximately 5 fold higher than APOE3 and APOE4 mice supporting 135 
hyperlipidemia in APOE2 mice as previously described [22]. In this study, plasma total 136 
FA was calculated by the addition of the measured FA expressed in concentrations. 137 
Plasma samples from APOE2 mice were cloudy and milky compared to the plasma of 138 
WT, APOE3 and APOE4 mice. 139 
 140 
3.3 FATP1 and FABP4 regulation in adipose tissues 
There was a weak, but significant APOE genotype effect on FATP1/-actin ratio 141 
(Fig. 1A, left panel; P = 0.047). In APOE4 mice, FATP1 level was at least 30% higher 142 
compared to the other genotypes. There was no significant APOE genotype effect for the 143 
ratio of FABP4/-actin in the adipose tissue (Fig. 1A, right panel). There were significant 144 
negative correlations between adipose tissue concentrations (µg/mg) of total n3 PUFA 145 
and FATP1 levels (r = −0.431, P = 0.003). There were no correlation between FABP4 146 
and any of the FA analysed in the adipose tissue neither was there between the levels of 147 
FATP1 or FABP4 and plasma FA profile. Using multiple regression analysis, LCFA 148 
concentrations (µg/mg) in adipose tissue were the only significant predictor of variation 149 
in FATP1 levels (R
2
 = 19.9%, P = 0.006). There was no relationship between FABP4 and 150 
the FA profile of adipose tissue. Plasma FA concentration was unable to predict any 151 
change in FATP1 or FABP4 protein levels (data not shown). 152 
3.4 FATP5 and FABP1 regulation in the liver 
There was a significant APOE genotype effect on FATP5/-actin ratio and 153 
FABP1/-actin ratio in the liver (P values of 0.037 and 0.031 respectively). FATP5 and 154 
FABP1 levels were more than 2 fold higher in APOE4 mice compared to APOE2 mice 155 
(Fig. 1B). Levels of FATP5 and FABP1 were also significantly higher in APOE3 mice 156 
compared to APOE2. There was no correlation between FA concentrations in the liver 157 
and FATP5 or FABP1 levels. However, the plasma concentration of total n3 PUFA was 158 
negatively correlated with FATP5 (r = −0.455, P = 0.044). Similarly, the plasma 159 
concentrations of AA was negatively correlated to FABP1 (r = −0.618, P = 0.004). Using 160 
multiple regression analysis, FATP5 was able to predict variation in the plasma 161 
concentrations of DHA (R
2
 = 25.4%, P = 0.024). Similarly, FABP1 levels predicted 162 
variation in the plasma concentration of AA (R
2
 = 38.2%, P = 0.004) (data not shown). 163 
3.5 Liver-type CTP1 levels according to APOE genotype 
There was a trend towards a genotype effect for the CPT1 in the liver (P = 0.073). 164 
Although, there was no significant genotype effect on CPT1, its mean concentration 165 
seemed to be higher in APOE4 mice (1.92 ± 0.10) compared to APOE2 (1.59 ± 0.14) and 166 
APOE3 mice (1.45 ± 0.22) (Fig. 2). Using Mann-Whitney U test to assess difference 167 
between two samples, concentration of CPT1 in the liver of APOE4 mice was 21% 168 
higher than APOE3 mice (P = 0.038).  169 
4.  DISCUSSION 
This study reports lower concentrations of n‒3 PUFA in the adipose and the liver 170 
of APOE4 mice compared to APOE3 mice. There was an APOE isoform-dependant 171 
effect for the levels of FATP in the liver and the adipose tissue and for FABP in the liver 172 
and a trend towards an APOE isoform-dependant effect on CPT1 concentration in the 173 
liver. 174 
The exact mechanism by which LCFAs are up-taken by cells is not clearly 175 
established and is still source of debates. Mitchell and Hatch [2] suggested a model 176 
involving the collaboration of four families of FA-handling proteins, among which 177 
FATPs and FABPs are major contributors. Briefly, LCFAs interact with membrane 178 
FATPs to be transported from the exoplasmic side to the cytoplasmic side of the cell 179 
membrane. The crucial mechanistic importance of FATPs for LCFAs internalization, 180 
form blood into organs and tissues, was confirmed through the use of FATP5 [25] and 181 
FATP1 [26] knockout (KO) mice models. Since FATP transport is bidirectional, FABP 182 
must then interact with internalized LCFAs in order to prevent their efflux back into 183 
circulation. Cytosolic tracking FABPs thereafter direct LCFAs towards metabolic routes 184 
such as mitochondrial β-oxidation [2, 14, 15, 27]. Thus, it was anticipated that the higher 185 
levels of FATPs and FABPs would result in higher LCFA uptake by tissues. In this study, 186 
there was a negative correlation between FATP5 levels and plasma LCFAs 187 
concentrations, independently of APOE genotypes. However, there was lower ALA, 188 
DHA and n3 PUFA in the liver and the adipose tissue of APOE4 mice compared to 189 
APOE3 mice. Therefore, we sought to determine whether this could be linked to higher 190 
β-oxidation of n3 PUFA based on our previous results in humans which suggested 191 
higher β-oxidation of DHA in APOE4 carriers [11]. Therefore, we quantified CPT1 192 
concentration in the liver according to APOE genotype. There was a trend towards an 193 
APOE isoform-dependant effect on CPT1 level where APOE4 mice tended to have 21% 194 
higher CPT1 levels than APOE3 mice. Considering that ALA is a preferred substrate for 195 
β-oxidation in humans and animals, [28-30], our results support the hypothesis of higher 196 
FA β-oxidation since APOE4 mice had significantly lower levels of ALA in the liver 197 
compared to APOE3 mice. However, DHA is usually highly conserved in animals and in 198 
humans based on our previous studies, but the lower level of DHA in the liver of APOE4 199 
mice support that there may be a shift in FA preference towards -oxidation pathway, 200 
explaining why DHA seems to be more catabolized in APOE4 carriers [11].  201 
The importance of the association between LCFAs degradation and APOE 202 
genotype resides in the recent association between low hepatic DHA and AD. Astarita et 203 
al [31, 32] reported lower DHA levels in the liver of AD patients compared to control 204 
subjects, which suggested an association between hepatic DHA homeostasis and 205 
cognition. Since carrying an allele of APOE4 is currently recognized as the most 206 
important risk factor of AD [5-7] higher -oxidation of n3 PUFAs may compromise the 207 
availability of DHA to support normal brain functions. It may also explain the lower 208 
brain level of DHA (%) in 13-months APOE4 mice compared to APOE2 mice reported 209 
by Vandal et al [9]. However, it seems possible to rebalance DHA homeostasis by 210 
providing a diet rich in DHA to APOE4 carriers [33]. This needs to be further 211 
investigated since -oxidation of DHA in APOE4 carriers fed 3 g/d of n3 PUFAs was 212 
lower compared to pre-supplementation [11], conversely to non-carriers for which 213 
feeding the supplement increases -oxidation of DHA compared to baseline [34]. 214 
This study reported that the uptake of circulating LCFAs by APOE2 mice was 215 
apparently inefficient and that CPT1 concentrations in the liver tended to be lower in 216 
APOE2-expressing animals compared to APOE4 (Fig. 2). These results are in line with 217 
the hypertriglyceridemia generally associated with APOE2 homozygous human carriers 218 
[22] and humanized APOE2 mice [35], as well as with the phenotype reported for CPT1 219 
KO mouse model [36]. Indeed, in this study, APOE2 mice add almost 5-fold higher total 220 
plasma lipids and plasma was white rather than light transparent yellow like the plasma 221 
of the other genotypes. As previously reported, lower hepatic and intramuscular -222 
oxidation have been report in the brain CPT1c isoform KO mice as well as elevated 223 
triacylglycerol content in liver and muscle in these mice [36]. Not much information is 224 
available in literature concerning the liver CPT1a isoform KO mice model for two major 225 
reasons: 1) complete inhibition of CPT1a enzyme is lethal to mice [37]; 2) CPT1a 226 
isoform bears a highly homologous primary sequence with its other known isoforms 227 
(CPT1b, muscle type isoform; CPT1c, brain type isoform) which gene-inactivation are 228 
non-lethal [38]. 229 
Using the same mouse model and the same diet, Vandal et al [9] recently reported 230 
40% higher relative % of n-3 PUFA and 34% higher DHA in plasma total lipids of 231 
APOE3 and APOE4 mice compared to APOE2 of 13-months of age. Similarly, in this 232 
study, the relative % of n-3 PUFA was nearly 40% higher in 8.5 to 12-month APOE3 233 
mice than APOE2 mice, but there was no difference between APOE4 and APOE2 mice 234 
(data not shown). The same pattern was observed for the relative % of DHA in plasma, 235 
with more than 30% higher DHA in APOE3 mice compared to APOE4 and APOE2 (data 236 
not shown). APOE2 mice have hyperlipidemia [35], supporting why in this study APOE2 237 
mice had 5 times higher plasma total lipids than APOE3 mice. Therefore, it seems more 238 
appropriate to express results in concentration rather than relative % of total FA when 239 
using the APOE-targeted replacement mouse model since relative % may mask potential 240 
higher lipid content in organs and plasma of these mice. 241 
There is now a need for defining whether FA preference for -oxidation is APOE 242 
isoform-dependent and whether it is possible to rebalance FA kinetics and metabolism in 243 
APOE4 carriers through high dose supplementation with DHA and/or EPA. This pathway 244 
could contribute in explaining why APOE4 carriers are at higher risk of developing AD. 245 
Unfortunately, we did not evaluate mice cognition in the present study and therefore, we 246 
cannot confirm this speculation − i.e. cognitive impairments in APOE4 mice [39, 40]. 247 
Also, the activity of FATPs, FABPs and CPT1 remains to be further investigated since 248 
only the levels, and not activities, were measured in the present study. Moreover, results 249 
obtained in humanized mice may not be translatable to humans and thus, caution is 250 
recommended with regard to interpretation of data obtained in humans. However, in 251 
support to the humanized mouse model used in our study, Raffaï et al [41] reported that 252 
introduction of apoE4 domain interaction into endogenous mouse APOE gene (i.e. 253 
through substitution of Thr-61 by Arg-61 resulted in a phenotype similar to that found in 254 
humans homozygous for APOE4 allele. 255 
In conclusion, this study showed an APOE isoform-dependant effect on adipose 256 
tissue, liver and plasma n3 PUFAs concentrations. Similarly, APOE-isoforms 257 
significantly modulated FATP levels in the adipose tissue and the liver and FABP levels 258 
in the liver. However, these APOE isoform-dependencies were not always in line with the 259 
unbalanced n‒3 PUFA profiles in organs. Therefore, besides APOE-isoform differences 260 
in FATP and FABP, other proteins are involved in maintaining n‒3 PUFA homeostasis in 261 
mice with different APOE-isoforms.  262 
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TABLE 1 
Macronutrients composition of the diets fed from weaning to 4-month and from 4 to 13-
months of age. 
  Diets at months  
(all mice, N= 45) 
  0-4 
a
  4-13 
b
 
Energy (kcal/g)  3.4  3.9 
Proteins (%, w/w)  18.9  20.3 
Carbohydrates (%, w/w)  57.3  66.0 
Fat (%, w/w)  6  5 
ALA (g/kg)  4.1  0.4 
EPA (g/kg)  0  0 
DHA (g/kg)  0  0 
LA (g/kg)  52.3  36.0 
AA (g/kg)  0  0 
Ratio n−6/n−3 PUFA  13  100 
a 
Tecklad Diet 2018 (Harlan Laboratory, Indianapolis, IN) 
b 
Diet D04042202 (Research Diets, Inc., New-Brunswick, NJ) 
TABLE 2 
Fatty acid concentrations in the adipose tissue of APOE-targeted replacement mice carrying human APOE isoforms or of Wild-type 
C57/BL6 mice 
a
 
  
ADIPOSE TISSUE (µg/mg of tissue)
 
P values
 
  
APOE2 APOE3
 
APOE4
 
WT
 
(for genotype) 
16:0
  
162.9 ± 8.8
 
147.4 ± 5.7 170.6 ± 9.7 145.4 ± 6.6
 
0.092 
18:0
  
11.1 ± 0.8 
A 
14.8 ± 1.4 
AB
 16.7 ± 1.9 
B
 11.9 ± 0.7 
A
 0.049 
16:1 n−7  58.8 ± 6.2 A 43.3 ± 5.1 A 64.0 ± 5.5 B 47.6 ± 2. 7 A 0.023 
18:1 n−9  299.8 ± 14.1 282.2 ± 9.6 307.7 ± 8.8 274.6 ± 8.9 0.118 
18:2 n−6  340.3 ± 25.2 355.8 ± 14.5 307.8 ± 24.3 317.9 ± 14.5 0.323 
20:4 n−6  3.8 ± 0.3 3.7 ± 0.1 3.9 ± 0.2 3.3 ± 0.3 0.378 
Total n−6 PUFA   344.5 ± 25.3 360.9 ± 14.6 312.8 ± 24.5 321.3 ± 14.7 0.322 
18:3 n−3  11.7 ± 2.2 AB 16.0 ± 1.4 A 8.9 ± 2.1 B 14.7 ± 1.6 A 0.031 
22:6 n−3  0.4 ± 0.3 B 1.2 ± 0.4 A 0.3 ± 0.1 B ND 0.014 
Total n−3 PUFA   12.0 ± 2.3 A 17.3 ± 1.6 A 9.2 ± 2.2 B 14.7 ± 1.6 AB 0.025 
Ratio n−6/n−3 PUFA   24.7 ± 1.3 27.3 ± 1.5 37.4 ± 8.0 22.6 ± 1.3 0.325 
a
 Mice were homozygous for human apolipoprotein E epsilon 2 (APOE2), or apolipoprotein E epsilon 3 (APOE3), or apolipoprotein E 
epsilon 4 (APOE4) and mice carrying endogenous murin-APOE gene (Wild-type; WT).  
ND: Not detected, Statistical differences were performed by a One-Way ANOVA or non-parametric analysis of variance (SPSS 
Statistics software, NY, USA). Signiﬁcance was set as P < 0.05 and the trend at P < 0.08. Fisher’s LSD or Mann-Whitney U post hoc 
analyses were performed to assess differences between genotype-groups. Different superscript letters within the same line indicate 
significant difference by APOE genotype. 
 
 
TABLE 3 
Fatty acid concentrations in the liver of APOE-targeted replacement mice carrying human APOE isoforms or of Wild-type C57/BL6 
mice 
a
 
  
LIVER (µg/mg of tissue)
 
P values
 
  
APOE2 APOE3
 
APOE4
 
WT
 
(for genotype) 
16:0
  
25.4 ± 3.5
 
26.5 ± 6.9 19.6 ± 2.4 28.2 ± 4.0
 
0.638 
18:0
  
3.0 ± 0.2
 
3.2 ± 0.2 3.1 ± 0.2 2.8 ± 0.2 0.378 
16:1 n−7  6.7 ± 1.3 8.7 ± 3.4 5.2 ± 0.9 7.5 ± 1.3 0.701 
18:1 n−9  33.7 ± 5.0 36.7 ± 12.2 33.9 ± 5.0 42.3 ± 5.9 0.917 
18:2 n−6  21.5 ± 1.8 21.3 ± 4.5 16.7 ± 2.0 18.1 ± 2.2 0.637 
20:4 n−6  5.3 ± 0.4 5.3 ± 0.5 4.9 ± 0.4 4.6 ± 0.5 0.718 
Total n−6 PUFA   27.9 ± 2.2 27.6 ± 5.1 22.5 ± 2.5 23.8 ± 2.7 0.654 
18:3 n−3  0.4 ± 0.1 B 0.7 ± 0.1 A 0.1 ± 0.1 B 0.3 ± 0.1 B 0.001 
22:6 n−3  2.4 ± 0.3 A 2.7 ± 0.3 A 1.8 ± 0.1 B 2.1 ± 0.2 AB 0.030 
Total n−3 PUFA   2.8 ± 0.4 AB 3.7 ± 0.4 A 2.0 ± 0.2 B 2.4 ± 0.3 B 0.004 
Ratio n−6/n−3 PUFA   13.5 ± 3.2 7.3 ± 0.7 12.5 ± 1.5 10.0 ± 0.4 0.051 
a
 Mice were homozygous for human apolipoprotein E epsilon 2 (APOE2), or apolipoprotein E epsilon 3 (APOE3), or apolipoprotein E 
epsilon 4 (APOE4) and mice carrying endogenous murin-APOE gene (Wild-type; WT).  
Statistical differences were performed by a One-Way ANOVA or non-parametric analysis of variance (SPSS Statistics software, NY, 
USA). Signiﬁcance was set as P < 0.05 and the trend at P < 0.08. Fisher’s LSD or Mann-Whitney U post hoc analyses were performed 
to assess differences between genotype-groups. Different uppercase superscript letters within the same line indicate significant 
difference by APOE genotype. 
  
TABLE 4 
Fatty acid concentrations in the plasma of APOE-targeted replacement mice carrying human APOE isoforms or of Wild-type C57/BL6 
mice 
a
 
  
PLASMA (µg/mL of tissue)
 
P values
 
  
APOE2 APOE3
 
APOE4
 
WT
 
(for genotype) 
16:0
  
1862.5 ± 299.4 
B 
377.4 ± 40.9 
A
 545.9 ± 105.7 
A
 499.6 ± 36.2 
A 
<0.001 
18:0
  
839.3 ± 107.9 
B 
273.1 ± 18.3 
A
 391.6 ± 67.3 
A
 337.8 ± 30.3 
A
 <0.001 
16:1 n−7  334.5 ± 85.7 B 40.1 ± 8.7 A 64.6 ± 19.4 A 77.5 ± 12.7 A <0.001 
18:1 n−9  2826.1 ± 642.4 B 308.3 ± 45.7 A 473.1 ± 86.4 A 456.6 ± 69.7 A <0.001 
18:2 n−6  3326.7 ± 625.1 B 642.6 ± 86.1 A 715.0 ± 140.3 A 663.1 ± 38.5 A <0.001 
20:4 n−6  1085.9 ± 168.4 B 379.8 ± 52.3 A 396.6 ± 44.6 A 487.6 ± 128.1 A <0.001 
Total n−6 PUFA   4557.1 ± 797.9 
B
 1066.5 ± 124.8 
A
 1170.6 ± 132.0 
A
 1237.0 ± 144.4 
A
 <0.001 
18:3 n−3  78.5 ± 31.5 B 6.6 ± 1.6 A 6.8 ± 2.7 A ND 0.002 
20:5 n−3  29.3 ± 14.5 B 10.2 ± 2.72 A  4.9 ± 1.9 A 9.3 ± 2.2 A 0.090 
22:6 n−3  23.7 ± 11.6 B 7.4 ± 2.0 A 6.3 ± 2.3 A 5.9 ± 2.2 A <0.001 
Total n−3 PUFA   420.9 ± 107.3 B 128.0 ± 12.0 A 133.5 ± 26.6 A 163.1 ± 23.1 A 0.001 
Ratio n−6/n−3 PUFA   15.7 ± 4.2 9.2 ± 1.4 10.7 ± 1.1 8.0 ± 0.8 0.134 
a
 Mice were homozygous for human apolipoprotein E epsilon 2 (APOE2), or apolipoprotein E epsilon 3 (APOE3), or apolipoprotein E 
epsilon 4 (APOE4) and mice carrying endogenous murin-APOE gene (Wild-type; WT).  
ND: Not detected, Statistical differences were performed by a One-Way ANOVA or non-parametric analysis of variance (SPSS 
Statistics software, NY, USA). Signiﬁcance was set as P < 0.05 and the trend at P < 0.08. Fisher’s LSD or Mann-Whitney U post hoc 
analyses were performed to assess differences between genotype-groups. Different uppercase superscript letters within the same line 
indicate significant difference by APOE genotype. 
LEGEND OF FIGURES 
FIG 1. (A.) Levels of fatty acid transport protein and binding protein of the 
adipose tissue (i.e. FATP1 and FABP4), over -actin. (B.) Levels of fatty acid transport 
protein and binding protein of the liver (i.e. FATP5 and FABP1), over -actin. FATP and 
FABP levels were obtained by Western blot and results are means ± SEM. For each 
proteins measured (i.e. FATP or FABP), three representative bands (N = 3) per genotype 
are presented in order to show the intragroup variations. Levels of tissue specific FATP 
and FABP in the adipose tissue and in the liver were analysed for statistical differences 
using non-parametric analysis of variance in SPSS (IBM Corp., Armonk, NY). 
Significant genotype effect was found for FATP1 (P = 0.047) in the adipose tissue and 
FATP5 (P = 0.037) and FABP1 (P = 0.031) in the liver. Pairwise comparisons were 
performed using Mann-Whitney U tests. P values < 0.05 were considered statistically 
significant. 
FIG 2. Liver carnitine palmitoyltransferase 1 (CPT1) concentrations (ng/mg) 
measured by enzyme-linked immunosorbent assay (ELISA). Results are presented in 
means ± SEM. Liver concentrations of CPT1 were analysed for statistical differences 
using ANOVA analysis of variance in SPSS (IBM Corp., Armonk, NY). There was a 
trend towards a genotype effect (P value = 0.073). *Pairwise comparison (Fisher’s LSD 
test) reported significant differences between APOE4 and APOE3 mice (P = 0.032). 
Dotted line is used to indicate the genotype trend (P value < 0.08). 
